AI's New Back Pain Gambit: Aclarion Courts Investors at LSI USA 2026

BROOMFIELD, Colo. – March 12, 2026 – As the MedTech world prepares to descend on Dana Point, California, for the exclusive LSI USA 2026 summit, one commercial-stage company is hoping to turn high-stakes networking into a new standard of care for millions. Aclarion, Inc. (Nasdaq: ACON), a healthcare technology firm, has announced that its CEO, Brent Ness, will be attending the influential gathering to meet with investors and potential partners. On the table for discussion is NOCISCAN, the company's pioneering platform that uses artificial intelligence to diagnose the precise source of chronic low back pain.

For Aclarion, the timing is critical. The company is navigating the challenging path from technological innovation to widespread commercial adoption. Mr. Ness's agenda of one-on-one meetings is not just a routine conference appearance; it represents a strategic push to secure the capital and alliances necessary to scale its operations and solidify its place in the competitive pain management market.

A Strategic Play in a High-Stakes MedTech Arena

The LSI USA summit is far from a typical trade show. Described as a highly curated environment for deal-making, it attracts a powerful mix of attendees: C-level executives from MedTech giants like Medtronic and Boston Scientific, managing partners from top-tier venture capital firms, and the CEOs of the most promising startups. For a company like Aclarion, gaining access to this inner circle is a pivotal opportunity.

The company is at a crucial juncture. While its stock saw a modest bump of nearly 5% on the news of its LSI attendance, it remains significantly below its 52-week high, reflecting the broader market's cautious stance on emerging MedTech firms. Investors are looking for more than just promising technology; they demand a clear path to profitability, strong clinical evidence, and a robust commercialization strategy. The meetings at LSI USA are Aclarion's chance to make that case directly to the people who write the checks and forge the partnerships that can make or break a company.

Attending LSI is about securing resources to fuel growth. Aclarion has reported progress in its CLARITY clinical trial, which aims to validate NOCISCAN's efficacy, and has noted growing scan volumes. However, scaling these efforts requires significant capital. Securing a new round of funding or a strategic partnership with a larger industry player could provide the non-dilutive capital and market access needed to accelerate the adoption of NOCISCAN, moving it from a niche technology to a widely accepted diagnostic tool.

Beyond the MRI: AI's New Frontier in Back Pain Diagnosis

Chronic low back pain affects hundreds of millions of people worldwide, creating a massive clinical and economic burden. A primary challenge has long been the diagnostic process itself. For decades, physicians have relied on Magnetic Resonance Imaging (MRI) to visualize the spine. While an MRI can reveal structural abnormalities like a herniated or degenerated disc, it often fails to answer the most critical question: is that specific disc the source of the patient's pain?

This diagnostic ambiguity often leads to a frustrating cycle for patients and physicians, involving trial-and-error treatments, from physical therapy and injections to invasive spinal fusion surgery that may not address the true pain generator. Aclarion aims to break this cycle by looking beyond structure and into chemistry.

The NOCISCAN platform leverages Magnetic Resonance Spectroscopy (MRS), a technology that analyzes the chemical composition of tissue. In a standard clinical workflow, MRS data is collected from a patient's lumbar discs during an MRI scan. This data is then securely uploaded to Aclarion's cloud platform, where proprietary AI algorithms get to work. The AI analyzes the data for specific chemical biomarkers that have been shown to be associated with painful, inflamed discs. Within minutes, the platform delivers a report to the physician, indicating whether each disc is likely painful or not.

This concept of "augmented intelligence" is key. NOCISCAN does not replace the physician's expertise but rather provides a powerful new data point. It gives surgeons and pain specialists objective, biomarker-based evidence to use alongside traditional imaging and clinical exams, allowing them to devise more precise and effective treatment plans.

The Human Cost and the Promise of Clarity

Behind the market statistics and technological specifications lies the profound human impact of chronic pain. Patients often endure years of debilitating discomfort, undergoing a "diagnostic odyssey" that can be as painful as the condition itself. They face a gauntlet of tests, conflicting medical opinions, and treatments that offer little relief, all while their quality of life diminishes.

The promise of Aclarion's technology is, as its CLARITY trial name suggests, clarity. For a patient who has been told they have multiple "bad discs," NOCISCAN could potentially pinpoint the single disc that is the true culprit. This information is transformative. It could mean the difference between a multi-level spinal fusion and a more targeted, less invasive procedure. It could give a patient the confidence to proceed with a recommended surgery or, conversely, help them avoid an unnecessary one.

By providing a more definitive diagnosis, the technology has the potential to shorten the path to effective relief. This not only improves patient outcomes and quality of life but also holds the promise of significant cost savings for the healthcare system by reducing expenditures on ineffective treatments and failed surgeries. The goal is to ensure the first intervention is the right intervention.

Navigating the Path to Market Adoption

Having an innovative technology is only the first step. The true test for Aclarion lies in its ability to integrate NOCISCAN into the complex ecosystem of American healthcare. This is where the strategy behind the LSI USA meetings becomes clear. The company is actively seeking partners to help navigate this path.

Potential collaborators range from large medical device manufacturers, who could incorporate NOCISCAN into their spine portfolios and leverage their vast sales and distribution networks, to national chains of imaging centers, which are essential for increasing the technology's availability. Partnerships with large hospital systems and orthopedic practice groups are also crucial for driving adoption and generating the real-world evidence needed to secure broad insurance reimbursement.

Aclarion has already begun to execute this strategy. In February, the company announced a commercial expansion with Source Healthcare to integrate NOCISCAN and generate real-world data, a tangible step toward building the evidence base that both clinicians and payers require. Now, as CEO Brent Ness prepares for his meetings in Dana Point, the objective is to replicate and scale that success. The discussions held at LSI USA could lay the groundwork for the next phase of Aclarion's growth, potentially accelerating the journey of its AI-powered technology from the conference room to the clinic, and finally to the patients who need it most.